THERE ARE MANY misconceptions about important cardiovascular metrics. Often people think their risk of heart disease and ...

Indeed, both non-HDL-C and apo B have been proposed as secondary treatment targets after LDL-C goals have been achieved. The EPIC-Norfolk investigation was used to select cases, who were ...

using an intact lipoprotein(a) assay, and 40.4, 70.0, and 68.9 percent, respectively, using an apolipoprotein(a)-based assay. Dose-dependent reductions in apolipoprotein B were seen for 8.9 ...

2 Department of Movement Sciences, Maastricht University, Maastricht, the Netherlands 3 Department of Endocrinology, University Hospital Groningen, Groningen, the Netherlands Correspondence to: Dr ...

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights ...

Compared with placebo, obicetrapib lowered LDL-C by 33% at day 84 ( P <.0001). Changes in other biomarkers, including high-density lipoprotein cholesterol (HDL-C), non-HDL-C, lipoprotein (a), ...

Researchers reveal the structural details of apoB100's interaction with LDL receptors, offering insights into LDL ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window TTHealthWatch is a weekly podcast from Texas Tech.

Finally, all statistical models included apo B to account for differences in the proatherogenic lipoprotein fraction. In the IDEAL study, we observed that plasma levels of HDL-C were indeed ...